Kazia Therapeutics (KZIA) Receivables (2009 - 2025)
Kazia Therapeutics' (KZIA) quarterly Receivables came in at $435566.3 in Q4 2025, up 260.85% YoY from $120705.3 in Q4 2024, and up 261.5% on a QoQ basis from $120487.9 in Q2 2025.
Kazia Therapeutics (KZIA) Receivables (2009 - 2025) Analysis & Trends
Kazia Therapeutics (KZIA) has 17 years of Receivables data on file, last reported at $435566.3 in Q4 2025.
- Quarterly Receivables rose 260.85% year-over-year to $435566.3 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $435566.3 (up 260.85% YoY) and the FY2025 annual result came in at $146105.2, down 94.5% from the prior year.
- Receivables rose to $435566.3 in Q4 2025, from $120487.9 in the prior quarter.
- In the past five years, Receivables ranged from a high of $2.9 million in Q4 2022 to a low of $55154.8 in Q4 2021.
- A 5-year average of $1.2 million and a median of $279387.6 in 2021 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables soared 5160.74% — and 2025, when it plunged 95.31%.
- Tracing KZIA's Receivables over 5 years: stood at $55154.8 in 2021, then soared by 5160.74% to $2.9 million in 2022, then dropped by 15.13% to $2.5 million in 2023, then sank by 95.1% to $120705.3 in 2024, then surged by 260.85% to $435566.3 in 2025.
- The last three Receivables figures came in at $435566.3 (Q4 2025), $120487.9 (Q2 2025), and $120705.3 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Kazia Therapeutics | 4.22 Bn | 4.22 Bn | - | 435,566.30 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 435,566.30 |
| Jun 30, 2025 | 120,487.90 |
| Dec 31, 2024 | 120,705.35 |
| Jun 30, 2024 | 2.57 Mn |
| Dec 31, 2023 | 2.46 Mn |
| Jun 30, 2023 | 2.68 Mn |
| Dec 31, 2022 | 2.90 Mn |
| Jun 30, 2022 | 101,710.10 |
| Dec 31, 2021 | 55,154.79 |
| Jun 30, 2021 | 123,208.82 |
| Dec 31, 2020 | 145,812.72 |
| Jun 30, 2020 | 1.26 Mn |
| Dec 31, 2019 | 635,370.46 |
| Jun 30, 2019 | 1.59 Mn |
| Dec 31, 2018 | 2.33 Mn |
| Jun 30, 2018 | 1.92 Mn |
| Jun 30, 2017 | 3.64 Mn |
| Dec 31, 2016 | 4.16 Mn |
| Jun 30, 2016 | 3.18 Mn |
| Dec 31, 2015 | 108,673.21 |